Evidence map›Paper›PMID 39676693›Full record

ArticleFuture oncology (London, England)2024

An early economic evaluation of active surveillance for low-risk ductal carcinoma

Danalyn Byng, Michael Schaapveld, Esther H Lips, Frederieke H van Duijnhoven, Jelle Wesseling, Wim H van Harten, Valesca P Retèl

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Future oncology (London, England), 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors.

Danalyn ByngDivision of Psychosocial Research & Epidemiology, The Netherlands Cancer Institute-Antoni van Leeuwenhoek Hospital, Amsterdam, CX 1066, The Netherlands.ORCID 0000-0002-8754-0530
Michael SchaapveldDivision of Psychosocial Research & Epidemiology, The Netherlands Cancer Institute-Antoni van Leeuwenhoek Hospital, Amsterdam, CX 1066, The Netherlands.
Esther H LipsDivision of Molecular Pathology, The Netherlands Cancer Institute-Antoni van Leeuwenhoek Hospital, Amsterdam, CX 1066, The Netherlands.
Frederieke H van DuijnhovenDivision of Surgical Oncology, The Netherlands Cancer Institute-Antoni van Leeuwenhoek Hospital, Amsterdam, CX 1066, The Netherlands.
Jelle WesselingDivision of Molecular Pathology, The Netherlands Cancer Institute-Antoni van Leeuwenhoek Hospital, Amsterdam, CX 1066, The Netherlands.
Wim H van HartenDivision of Psychosocial Research & Epidemiology, The Netherlands Cancer Institute-Antoni van Leeuwenhoek Hospital, Amsterdam, CX 1066, The Netherlands.ORCID 0000-0001-9580-0489
Valesca P RetèlDivision of Psychosocial Research & Epidemiology, The Netherlands Cancer Institute-Antoni van Leeuwenhoek Hospital, Amsterdam, CX 1066, The Netherlands.ORCID 0000-0002-5624-3234

Funding

Cancer Research UK C38317KWF Kankerbestrijding A24043
6 · The paper itself

Abstract

PubMed holds no abstract for this paper.

Indexed as

Breast NeoplasmsCarcinoma, Intraductal, NoninfiltratingWatchful WaitingAgedCost-Benefit AnalysisFemaleHumansMarkov ChainsMastectomy, SegmentalMiddle AgedQuality-Adjusted Life Yearsactive surveillancebiomarkerscost–effectivenessductal carcinoma in situearly economic evaluation

Identifiers

PMID39676693
PMCPMC12219084

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.